BMRN - BIOMARIN PHARMACEUTICAL INC
IEX Last Trade
66.69
-0.115 -0.172%
Share volume: 18,392
Last Updated: Fri 27 Dec 2024 08:29:55 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$66.80
-0.12
-0.17%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-04 | 2022-10-28 | 2023-02-27 | 2023-04-28 | 2023-08-02 | 2023-11-02 | 2024-02-26 | 2024-04-26 | |
| Assets | |||||||||
| Total Assets | 6.146 B | 6.264 B | 6.375 B | 6.434 B | 6.563 B | 6.758 B | 6.842 B | 6.873 B | |
| Current Assets | 2.518 B | 2.683 B | 2.751 B | 2.842 B | 2.950 B | 2.955 B | 2.956 B | 2.985 B | |
| Inventories | 802.315 M | 839.460 M | 894.083 M | 918.921 M | 975.546 M | 1.032 B | 1.107 B | 1.138 B | |
| Other Current Assets | 139.029 M | 149.851 M | 104.521 M | 173.180 M | 193.391 M | 224.806 M | 141.391 M | 163.287 M | |
| Short Term Investments | 139.029 M | 149.851 M | 104.521 M | 173.180 M | 193.391 M | 224.806 M | 141.391 M | 163.287 M | |
| Total Receivables | 466.507 M | 419.622 M | 461.316 M | 597.913 M | 610.222 M | 572.498 M | 633.704 M | 637.163 M | |
| Current Cash | 1.110 B | 1.274 B | 1.292 B | 1.152 B | 1.171 B | 1.126 B | 1.074 B | 1.047 B | |
| Total Non-current Assets | 3.628 B | 3.581 B | 3.624 B | 3.592 B | 3.613 B | 3.803 B | 3.886 B | 3.888 B | |
| Property Plant Equipment | 1.049 B | 1.052 B | 1.073 B | 1.068 B | 1.067 B | 1.067 B | 1.066 B | 1.060 B | |
| Other Assets | 151.797 M | 151.788 M | 176.236 M | 150.057 M | 144.168 M | 165.069 M | 171.538 M | 184.790 M | |
| Intangible Assets | 369.368 M | 354.024 M | 338.569 M | 325.989 M | 310.343 M | 302.476 M | 294.701 M | 279.653 M | |
| Goodwill | 196.199 M | 196.199 M | 196.199 M | 196.199 M | 196.199 M | 196.199 M | 196.199 M | 196.199 M | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 6.146 B | 6.264 B | 6.375 B | 6.434 B | 6.563 B | 6.758 B | 6.842 B | 6.873 B | |
| Total liabilities | 1.641 B | 1.696 B | 1.772 B | 1.775 B | 1.780 B | 1.861 B | 1.890 B | 1.799 B | |
| Total current liabilities | 464.727 M | 521.020 M | 588.884 M | 598.231 M | 597.231 M | 1.163 B | 1.177 B | 1.088 B | |
| Accounts Payable | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 95.260 M | 92.473 M | 100.015 M | 92.415 M | 98.120 M | 105.457 M | 119.935 M | 117.352 M | |
| Current long term debt | 0.000 | 0.000 | 2.287 M | 0.000 | 0.000 | 493.398 M | 494.016 M | 494.357 M | |
| Long term debt | 1.081 B | 1.082 B | 1.083 B | 1.084 B | 1.085 B | 592.586 M | 593.095 M | 593.605 M | |
| Other liabilities | 95.260 M | 92.473 M | 100.015 M | 92.415 M | 98.120 M | 105.457 M | 119.935 M | 117.352 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 4.505 B | 4.569 B | 4.603 B | 4.659 B | 4.783 B | 4.897 B | 4.952 B | 5.074 B | |
| Common stock | 185.254 M | 185.597 M | 186.223 M | 186.667 M | 187.948 M | 188.219 M | 188.502 M | 188.866 M | |
| Retained earnings | -777.227 M | -788.949 M | -789.199 M | -738.347 M | -682.307 M | -641.929 M | -621.554 M | -532.892 M |